Asset Details
Do you wish to reserve the book?
Reevaluating PSA Testing Rates in the PLCO Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reevaluating PSA Testing Rates in the PLCO Trial
Do you wish to request the book?
Reevaluating PSA Testing Rates in the PLCO Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reevaluating PSA Testing Rates in the PLCO Trial
2016
Overview
The PLCO trial generated data that argue against PSA screening. However, participants in the control group also reported being screened. An analysis of health questionnaires suggests that more than 80% of controls had been tested within the previous 3 years.
To the Editor:
In March, the Centers for Medicare and Medicaid Services temporarily suspended the development of a proposed “Non-Recommended Prostate-Specific Antigen (PSA)–Based Screening” measure that would discourage PSA screening in all men. The U.S. Preventive Services Task Force (USPSTF) is currently in the process of updating its recommendations for prostate-cancer screening. The decisions made by these two organizations are likely to determine the fate of PSA screening in the United States.
Much of the controversy surrounding screening revolves around the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which randomly assigned men to annual prostate-cancer screening or usual . . .
Publisher
Massachusetts Medical Society
